Clinical Profile of Documented Diabetic Peripheral Neuropathy by GLP-1-Based Medication Status: A Cross-Sectional Study
Anca Cristina Ferician, Timea Claudia Ghitea, Mihaela Simona Popoviciu, Åke Sjöholm · 2026
Read Clinical Profile of Documented Diabetic Peripheral Neuropathy by GLP-1-Based Medication Status: A Cross-Sectional Study by Anca Cristina Ferician, Timea Claudia Ghitea, Mihaela Simona Popoviciu, Åke Sjöholm (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13609424.txt.
Description
Anca Cristina Ferician and three colleagues profile diabetic nerve damage patients by whether records list a modern GLP-1-based medicine. These drugs, including semaglutide and the dual agent tirzepatide, are prescribed more often to sicker patients, so simple comparisons mislead. Working from a Romanian county hospital's exports covering February 2024 to February 2026, the team aggregated records for 4,120 patients.
GLP-1-based medicines appeared in 20.7 percent of records. That subgroup had diabetes about three years longer and carried more recorded conditions. Heart failure showed in 35.7 percent of them against 22.2 percent of the rest, and lower-limb amputation in 3.3 against 1.2 percent. Adjustment softened but did not erase the heart failure gap. The files held no dates for treatment or outcomes, so the authors insist the study cannot show these drugs help or harm nerves. What it shows is that a GLP-1 record flags a complex subgroup planners should not average away.
Catalog record
| CREATOR | Anca Cristina Ferician, Timea Claudia Ghitea, Mihaela Simona Popoviciu, Åke Sjöholm |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |